BIA (BioIndustry Association) welcomes move to revamp UK pre-emption policy:
This article was originally published in Clinica
Executive Summary
The UK's BioIndustry Association (BIA) has welcomed a report reviewing current pre-emption guidelines and whether they inhibit public companies from raising adequate funding from the capital markets. The BIA highlighted the report's criticism of the "blanket approach to disapplying pre-emption rights...due to a rigid interpretation of the guidelines". The BIA welcomes the recommendations of report author Paul Myners that the guidelines should be replaced to allow for a "case-by-case engagement between a company's directors and shareholders" and that there be a more proactive monitoring of their application, under a new pre-emption group. The current fund-raising thresholds stand at 5% of issued share capital per year, and up to 7.5% over a three-year period. The BIA wants the 5% limit raised to 20%.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.